A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application to the U.S. FDA, seeking approval of ensifentrine as a maintenance therapy. In the latest episode of Optimum Perspectives podcast, Eva Haas caught up with Chris Martin, Senior Vice President of Commercial, who […]
YOUNG biotech companies need “patient investors” with “deep pockets” to weather today’s financial storms, the head of Novo Holdings Seed Investments has told the Optimum Perspectives podcast. In an in-depth interview, Søren Møller said fledgling firms should accept it might be some time before investor confidence returns to the sector – and they need to […]
Calliditas is one of European biopharma’s big success stories, bringing a rare disease drug to market and commercializing it using its own sales force. Richard Staines from Optimum Strategic Communications spoke with CEO Renée Aguiar-Lucander who outlined the challenges the company has faced on its journey. Lengthy experience as a life science investor has helped […]
In episode four of Optimum Perspectives Podcast, our in-house IR expert, ex-Fund Manager Eva Haas interviewed Dan Mahony, Chairman of the BioIndustry Association (BIA), following his appointment as UK Life Sciences Investment Envoy to hear his plans for championing the UK’s Life Sciences industry. Dan’s circuitous and unplanned journey to his current role involved among […]
THE CHAIN PODCAST Our Co-Founder and CSO Jane Osbourn was delighted to speak with her longtime friend Ahuva Nissim, antibody and therapeutic engineering professor at William Harvey Research Institute, Queen Mary University of London, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent […]
